Triamcinolone
As of the edition of 20 October 2026, Triamcinolone is a small molecule: marketed, first approved in 1959 (CH); acts on NR3C1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Aristocort
- First approved
- 7 January 1959 (CH)
- Approvals on record
- 12 in 4 regions
- Holder of the most recent approval
- Delcor Asset; 5 holders in all
- Registered trials
- 89, 15 stopped early
- Disease areas
- Bones, joints and muscles; Skin and connective tissue; Eye; Immune system; Inherited and neonatal; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| NR3C1 | Glucocorticoid receptor | P04150 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 27 | 16 | 3 | 2 |
| Phase 1 | 6 | 1 | 3 | 1 |
| Phase 2 | 11 | 6 | 0 | 3 |
| Phase 3 | 18 | 8 | 2 | 4 |
| Phase 4 | 27 | 15 | 4 | 5 |
| All trials | 89 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Astellas | Acquired holder | 2005 to now |
| Delcor Asset | Acquired holder | 2015 to now |
| Bristol Myers Squibb | Later holder | |
| Pfizer | Earlier holder |